跳至主要内容
临床试验/ACTRN12605000257662
ACTRN12605000257662
已完成
3 期

A Follow-up Study to determine the efficacy and safety profile of a Pathway formulation in lowering lipid levels in primary hypercholesteremia over a 24-week period. of a Complementary Medicine Formulation in Primary Hypercholesterolemia

Pathways0 个研究点目标入组 30 人2005年9月1日

概览

阶段
3 期
干预措施
未指定
疾病 / 适应症
Primary hypercholesteremia
发起方
Pathways
入组人数
30
状态
已完成
最后更新
6年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2005年9月1日
结束日期
待定
最后更新
6年前
研究类型
Interventional
性别
All

研究者

发起方
Pathways

入排标准

入选标准

  • 1\. LDL cholesterol ³3\.5 and 5\.7mmol/L 2\. Body mass index 32kg/m23\. Subject is willing to cease all medications over the course of the study, excluding medications for acute conditions such as pain or dyspepsia.

排除标准

  • 1\. Individuals with triglyceride levels \>4mmol/L2\. Individuals with a total cholesterol level \>10 mmol/L3\. Individuals with clinically abnormal liver function tests at baseline (measured at visit 2\)4\. Women who are pregnant or unwilling to use birth control for the period of the study5\. Individuals with diabetes6\. Individuals with hyperthyroidism7\. Individuals with obstructive bile duct disease8\. Individuals with metabolic disorders other than primary hypercholesterolaemia, includingphytosterolaemia9\. Individuals who smoke10\. Individuals with cardiovascular disease11\. Subjects unwilling to comply with the study protocols12\. Subjects with poor venous access13\. Any other condition which in the opinion of the researchers could compromise the study.

结局指标

主要结局

未指定

相似试验